Placenta-derived cells boost the efficiency of islet transplants for treating type I diabetes
To regulate blood glucose levels, our bodies need hormones produced by cells in the islets of Langerhans, in the pancreas: insulin, which reduces blood glucose, and glucagon, which has the opposite effect. In patients with type 1 diabetes, regulation fails because their immune system destroys the insulin-producing beta cells. Transplants of healthy islets, with functioning beta cells, can be the only solution for severely-affected patients, but this procedure is difficult, often requiring multiple donors before successful implantation. Working to improve the process, researchers added amniotic epithelial cells (AECs), extracted from the placenta, to islet cells, before transplanting the resulting clusters into diabetic mice. Compared to regular islets (pictured, left, with beta cells in blue, glucagon-producing alpha cells in red), these 'super-islets' (right, with AECs in green) integrated more successfully, and thus brought the mice’s blood glucose levels down faster, suggesting that using AECs in transplants could improve prospects for patients.
Written by Emmanuelle Briolat
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.